STOCK TITAN

Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Apnimed (Nasdaq: APMD) reported a third-quarter net loss of $29.524 million while advancing preparations for a potential launch of AD109.

Related-party revenue fell to $2.480 million from $8.802 million a year earlier. Research and development expenses rose to $11.812 million from $9.754 million, while general and administrative expenses increased to $22.628 million from $6.045 million. Cash and cash equivalents totaled $351.8 million at September 30, 2026, following an August IPO that raised approximately $198.9 million net. Apnimed expects its cash to fund a potential U.S. launch and operations into the second quarter of 2028.

AD109, proposed as Oxnimbi for adults with obstructive sleep apnea, remains under FDA review with a February 28, 2027 decision goal date. Launch preparations remain subject to approval. Nine-month net income was $164.130 million, including an investment-sale gain.

Loading...
Loading translation...
14 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointAugust 2026 IPO raised approximately $198.9 million in net proceeds. 28% of market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Apnimed expects cash to fund a potential U.S. launch and operations into the second quarter of 2028.
  • Moderate pointAD109 completed two Phase 3 trials for mild, moderate and severe obstructive sleep apnea.
  • Moderate pointNine-month related-party revenue rose to $99.374 million from $29.043 million a year earlier.
  • Moderate pointNine-month net income reached $164.130 million, versus a $109.030 million loss a year earlier.
  • Moderate pointNine-month research and development expenses fell to $29.816 million from $49.179 million a year earlier.
8 minor points
  • Minor pointCash and equivalents increased to $351.826 million at September 30, 2026, from $41.890 million at year-end.
  • Minor pointCommercial preparations advanced across payer engagement, team build-out, manufacturing and distribution for a potential U.S. launch.
  • Minor pointNine-month diluted earnings were $9.63 per share, versus a $22.91 loss a year earlier.
  • Minor pointNine-month investment-sale gain totaled $85.380 million.
  • Minor pointNine-month deposit-liability reversal produced a $57.120 million gain.
  • Minor pointRelated-party service costs fell to $0.245 million in Q3 and $3.615 million over nine months, year over year.
  • Minor pointQ3 other income increased to $2.681 million from $0.263 million a year earlier.
  • Minor pointStockholders’ equity reached $284.757 million at September 30, versus a $372.783 million deficit at year-end.

Negative

  • Moderate pointQ3 net loss widened to $29.524 million from $10.910 million a year earlier.
  • Moderate pointQ3 related-party revenue fell to $2.480 million from $8.802 million a year earlier.
  • Moderate pointQ3 research and development expenses rose to $11.812 million from $9.754 million a year earlier.
  • Moderate pointQ3 general and administrative expenses rose to $22.628 million from $6.045 million a year earlier.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.AD109 remains under FDA review; the potential U.S. launch depends on approval.
  • Moderate pointDebt totaled $39.059 million at September 30, 2026, versus none at December 31, 2025.
2 minor points
  • Minor pointNine-month general and administrative expenses rose to $41.808 million from $16.868 million a year earlier.
  • Minor pointRevenue interest liability totaled $10.297 million at September 30, 2026, versus none at year-end.

News Explained

Apnimed reported 4,781,256 common shares outstanding on December 31, 2025 and 41,630,779 on September 30, 2026; the higher share count reduces existing holders’ percentage ownership, absent offsetting changes.

Key Figures

PDUFA goal date: February 28, 2027 Cash and cash equivalents: $351.8 million Related-party revenue: $2.480 million vs. $8.802 million +3 more
PDUFA goal date
February 28, 2027
AD109 NDA remains under FDA review
Cash and cash equivalents
$351.8 million
As of September 30, 2026
Related-party revenue
$2.480 million vs. $8.802 million
Three months ended September 30, 2026 vs. 2025
Research and development expenses
$11.8 million vs. $9.8 million
Third quarter 2026 vs. third quarter 2025; increased 20%
General and administrative expenses
$22.6 million vs. $6.0 million
Third quarter 2026 vs. third quarter 2025; increase was greater than 100%
Net loss
$29.5 million vs. $10.9 million
Third quarter 2026 vs. third quarter 2025

Previous Earnings Reports

1 past event · Latest: Sep 08
Same Type 1 event
  1. Sep 08

    NDA acceptance

    24h Move
    -2.5%

    FDA accepted the AD109 NDA and assigned a February 28, 2027 PDUFA goal date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nda, pdufa, osa, antimuscarinic
4 terms
nda regulatory
"New Drug Application (“NDA”) for AD109"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
pdufa regulatory
"Prescription Drug User Fee Act (“PDUFA”) goal date"
PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.
osa medical
"adults with obstructive sleep apnea (“OSA”)"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
antimuscarinic medical
"a novel antimuscarinic"
A class of drugs that block muscarinic acetylcholine receptors, which are proteins on nerve and muscle cells that respond to the neurotransmitter acetylcholine. By reducing these signals, antimuscarinics relax smooth muscle and reduce secretions, so they are used for conditions like overactive bladder, some respiratory disorders, and gastrointestinal spasms. For investors, the term matters because antimuscarinic compounds have specific efficacy and side‑effect profiles, regulatory pathways, and market demand that affect a drug candidate's commercial and approval prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date
  • Commercial readiness activities advance in preparation for a potential U.S. launch
  • Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA
  • $351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028

CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We are in a transformational period at Apnimed,” said Kevin Lind, Chief Executive Officer of Apnimed. “With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story. At CHEST, we presented new analyses in postmenopausal women, on baseline hypoxic burden as a potential marker of blood pressure response, and on patient-reported outcomes. We believe this growing body of evidence is important to establishing the potential role of Oxnimbi for the millions of adults with OSA who remain untreated.”

Recent Highlights and Upcoming Milestones

  • The NDA for AD109 (proposed proprietary name Oxnimbi) for the treatment of adults with obstructive sleep apnea (“OSA”) remains under review by the FDA. The FDA has assigned a PDUFA goal date of February 28, 2027.
  • Continued to advance commercial readiness activities, including market access and payer engagement, commercial team and go-to-market build-out, and manufacturing and distribution preparation, to support a potential U.S. launch of Oxnimbi, subject to FDA approval.
  • Presented five abstracts at the American College of Chest Physicians’ CHEST 2026 Annual Meeting: three featuring Phase 3 AD109 data, including two late-breakers and one on patient-reported outcomes, and two real-world studies on the burden of OSA. The meeting also featured a CHEST-led panel discussion on the results of the Phase 3 SynAIRgy and LunAIRo trials and their potential application to OSA management.
  • Completed its upsized initial public offering in August 2026, raising approximately $198.9 million in net proceeds. With $351.8 million in cash and cash equivalents as of September 30, 2026, the Company is well positioned to support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA.

Third Quarter Financial Results

Cash Position

Apnimed reported cash and cash equivalents of approximately $351.8 million at September 30, 2026.

Research and Development Expenses

Research and development expenses were $11.8 million for the three months ended September 30, 2026, an increase of $2.0 million, or 20%, compared to $9.8 million for the three months ended September 30, 2025. The net increase was primarily due to:

  • An increase of $2.1 million in medical affairs expense, driven by increased Key Opinion Leader (“KOL”) engagement in 2026;
  • Higher employee-related expenses of $1.3 million; and
  • Higher stock-based compensation of $0.6 million.

These increases were partially offset by $2.0 million of lower clinical trial expense related to AD109 (proposed proprietary name Oxnimbi), as we focus on commercial launch.

General and Administrative Expenses

General and administrative expenses were $22.6 million for the three months ended September 30, 2026, an increase of $16.6 million, or greater than 100%, compared to $6.0 million for the three months ended September 30, 2025. The net increase was primarily related to:

  • $8.1 million in professional services incurred related to business consulting and contract negotiations, IT infrastructure, and increased salary and related employee expenses due to increased headcount;
  • $4.0 million in infrastructure to prepare the Company, the market, and the Company’s brand for the potential launch of AD109 (proposed proprietary name Oxnimbi), if approved, including key areas such as education on the unmet needs in OSA, pricing strategy, forecast estimates, market access planning, product positioning and stakeholder messaging; and
  • $4.4 million in stock-based compensation related to increased headcount and modifications of certain equity awards.

Other Income

Other income was $2.7 million for the three months ended September 30, 2026, an increase of $2.4 million, or greater than 100%, compared to $0.3 million for the three months ended September 30, 2025. The net increase was primarily related to:

  • A $1.6 million increase in interest income; and
  • A $1.2 million increase in fair value of long-term debt.

These increases were partially offset by a $0.3 million change in fair value of revenue interest liability.

Net Loss

Net loss was $29.5 million for the quarter ended September 30, 2026, compared to a net loss of $10.9 million for the quarter ended September 30, 2025. The increase was primarily attributable to the factors impacting the Company’s expenses and other income described above.

About AD109 / Oxnimbi

AD109 is Apnimed’s investigational drug candidate, with a proposed proprietary name Oxnimbi. The proposed name remains subject to final FDA review and acceptance and may change. AD109 is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in adults with OSA. It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 is intended to be a once-daily oral pill taken at bedtime that is designed to lower the complexity of treating OSA. AD109 may offer an oral solution to help improve oxygenation and health for adults living with OSA. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed’s NDA for AD109 is under review by the FDA and was assigned a PDUFA goal date of February 28, 2027. There can be no assurances that AD109 will be approved by the FDA by the PDUFA goal date, or at all.

About Apnimed

Apnimed is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Apnimed believes the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for adults with OSA. Apnimed believes that adults with OSA would benefit from having multiple treatment options with differing mechanisms to more fully address the heterogeneity of OSA’s disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention and expand the reach of diagnosis and treatment.

Apnimed is advancing its product candidate, AD109 (proposed proprietary name Oxnimbi), which is designed to improve oxygenation in adults living with OSA. Apnimed believes that Oxnimbi could become the catalyst for a new oral treatment paradigm for OSA, which has historically been limited to devices or invasive surgeries.

Learn more at apnimed.com or follow us on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “envisions,” “will,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, without limitation, statements regarding our expectations as to commercial readiness activities and launch, the potential approval and commercialization of Oxnimbi, the potential acceptance of Oxnimbi as the proprietary name for AD109, the clinical and therapeutic potential of Oxnimbi (including to address or catalyze a new treatment paradigm for OSA), the size of the commercial opportunity for Oxnimbi, the occurrence and timing of the PDUFA goal date for Oxnimbi, and other statements that are not historical facts. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.

Forward-looking statements are based on our current expectations, estimates and projections only as of the date of this release and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in biopharmaceutical product development; our ability to execute on our strategy, including obtaining the requisite regulatory approvals on the expected timeline, if at all; risks related to our financial condition and the need for substantial additional funding in order to complete development activities and commercialize Oxnimbi; risks related to the competitive landscape for OSA products; our ability to attract, integrate and retain key personnel; risks related to regulatory developments and approval processes of the FDA and comparable foreign regulatory authorities; and risks related to establishing and maintaining our intellectual property protections. These and other risks and uncertainties concerning our business and operations are described more fully in the section titled “Risk Factors” of our most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements contained in this announcement are made as of this date, and Apnimed undertakes no duty to update such information except as required under applicable law.

Media Contact:
media@apnimed.com

Investor Contact:
ir@apnimed.com

APNIMED, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share amounts)
 
 September 30, 2026 December 31, 2025
ASSETS     
CURRENT ASSETS:     
Cash and cash equivalents$351,826  $41,890 
Prepaid research and development costs 1,881   1,541 
Accounts receivable 588   959 
Prepaid expenses and other current assets 6,661   665 
Total current assets 360,956   45,055 
PROPERTY AND EQUIPMENT, NET 46   66 
ASSETS HELD FOR SALE –   26,893 
CONTINGENT ASSET 9,812   – 
OPERATING LEASE RIGHT-OF-USE ASSET 652   835 
OTHER ASSETS 24   24 
TOTAL ASSETS$371,490  $72,873 
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)     
CURRENT LIABILITIES:     
Accounts payable$4,326  $1,788 
Accrued expenses and other current liabilities 15,068   11,026 
Operating lease liability 273   250 
Short-term deferred revenue 17,296   97,812 
Total current liabilities 36,963   110,876 
LONG TERM LIABILITIES:     
Operating lease liability, net of current 414   623 
Convertible notes –   40,646 
Debt 39,059   – 
Revenue interest liability 10,297   – 
Deposit liability –   57,120 
Deferred revenue –   15,244 
TOTAL LIABILITIES 86,733   224,509 
COMMITMENTS AND CONTINGENCIES (NOTE 7)     
Convertible Preferred Stock, $0.00001 par value, no shares and 25,934,116 shares authorized as of September 30, 2026 and December 31, 2025, respectively; no shares and 25,934,116 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. Liquidation preference of $0 and $224,518 as of September 30, 2026 and December 31, 2025, respectively. –   221,147 
STOCKHOLDERS’ EQUITY (DEFICIT):     
Preferred stock, $0.00001 par value, 10,000,000 and no shares authorized as of September 30, 2026 and December 31, 2025, respectively; no shares issued or outstanding as of either date. –   – 
Common stock, $0.00001 par value, 500,000,000 shares authorized as of September 30, 2026 and 45,627,228 (42,481,983 Class A, 2,948,668 Class B, and 196,577 Class C) shares authorized as of December 31, 2025; 41,630,779 shares issued and outstanding as of September 30, 2026 and 4,781,256 (1,832,588 Class A, 2,752,091 Class B, and 196,577 Class C) shares issued and outstanding as of December 31, 2025. 1   1 
Additional paid-in capital 517,970   24,560 
Accumulated deficit (233,214)  (397,344)
Total stockholders’ equity (deficit) 284,757   (372,783)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)$371,490  $72,873 


APNIMED, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except share and per share amounts)
 
 Three Months Ended September 30, Nine Months Ended September 30,
 2026 2025  2026 2025 
REVENUE – RELATED PARTY$2,480 $8,802  $99,374 $29,043 
OPERATING EXPENSES:         
Research and development 11,812  9,754   29,816  49,179 
General and administrative 22,628  6,045   41,808  16,868 
Cost of services – related party 245  1,987   3,615  5,028 
Total operating expenses 34,685  17,786   75,239  71,075 
INCOME (LOSS) FROM OPERATIONS (32,205) (8,984)  24,135  (42,032)
OTHER INCOME (EXPENSES):         
Interest income 1,814  263   3,002  1,003 
Gain on reversal of deposit liability –  –   57,120  – 
Change in fair value of long-term debt 1,208  –   (451) – 
Change in fair value of revenue interest liability (260) –   (720) – 
Change in fair value of convertible notes –  –   1,315  – 
Other expense (81) –   (2,819) – 
Total other income 2,681  263   57,447  1,003 
NET INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (29,524) (8,721)  81,582  (41,029)
Income tax expense –  –   –  – 
NET INCOME (LOSS) FROM CONTINUING OPERATIONS (29,524) (8,721)  81,582  (41,029)
Gain on sale of equity method investment –  –   85,380  – 
Loss from discontinued operations –  (2,189)  (2,832) (68,001)
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS –  (2,189)  82,548  (68,001)
NET INCOME (LOSS)$(29,524)$(10,910) $164,130 $(109,030)
          
Net income (loss) per share – Basic:         
Continuing operations$(1.05)$(1.83) $6.46 $(8.62)
Discontinued operations –  (0.46)  6.54  (14.29)
Basic net income (loss) per share$(1.05)$(2.29) $13.00 $(22.91)
          
Net income (loss) per share – Diluted:         
Continuing operations$(1.05)$(1.83) $4.75 $(8.62)
Discontinued operations –  (0.46)  4.88  (14.29)
Diluted net income (loss) per share$(1.05)$(2.29) $9.63 $(22.91)
          
Weighted average common shares outstanding, basic 28,019,494  4,768,110   12,621,882  4,756,996 
Weighted average common shares outstanding, diluted 28,019,494  4,768,110   16,903,129  4,756,996 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the FDA decision expected for Apnimed’s AD109?

The FDA has assigned AD109 a February 28, 2027 review goal date. The application seeks approval to treat adults with obstructive sleep apnea. Oxnimbi is the proposed brand name, which remains subject to final FDA acceptance.

What was Apnimed’s third-quarter 2026 loss per share?

Apnimed reported a basic and diluted net loss of $1.05 per share, compared with $2.29 per share a year earlier. Weighted-average common shares outstanding were 28,019,494, compared with 4,768,110 in the prior-year quarter.

Keep reading